Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Aarti Jibodh

Showing results (1-10 of 2) with videos related to

Pageof 1
Sort By:
Journal of Immunology (Baltimore, Md. : 1950)|February 2, 2010
Activation-induced cytidine deaminase splice variants are defective because of the lack of structural support for the catalytic siteFebe van Maldegem, R Aarti Jibodh, Remco van Dijk, et al.
Cancers|June 19, 2019
Phase I Dose Escalation Study with Expansion Cohort of the Addition of Nab-Paclitaxel to Capecitabine and Oxaliplatin (CapOx) as First-Line Treatment of Metastatic Esophagogastric Adenocarcinoma (ACTION Study)Sandor Schokker, Stephanie O van der Woude, Jessy Joy van Kleef, et al.
Pageof 1

Showing results (1-10 of 2) with videos related to

Sort By:
Pageof 1
Journal of Immunology (Baltimore, Md. : 1950)|February 2, 2010
Activation-induced cytidine deaminase splice variants are defective because of the lack of structural support for the catalytic siteFebe van Maldegem, R Aarti Jibodh, Remco van Dijk, et al.
Cancers|June 19, 2019
Phase I Dose Escalation Study with Expansion Cohort of the Addition of Nab-Paclitaxel to Capecitabine and Oxaliplatin (CapOx) as First-Line Treatment of Metastatic Esophagogastric Adenocarcinoma (ACTION Study)Sandor Schokker, Stephanie O van der Woude, Jessy Joy van Kleef, et al.
Pageof 1